This multicentre study investigated the dynamics of thrombospondin 2 (TSP2) levels during direct‐acting antiviral (DAA) therapy in hepatitis C virus (HCV) infected patients and evaluated TSP2's potential as a predictive marker for hepatocellular carcinoma (HCC). The gene discussed is THBS2; the disease is hepatocellular carcinoma.